Goldman Sachs analyst Matthew Sykes downgraded PacBio to Neutral from Buy with a price target of $2.50, down from $7, following the preliminary Q1 results. The company expected flat to slightly down Revio system shipments in Q1 versus Q4, but reported 28 shipments in Q1 compared to 44 in Q4, the analyst tells investors in a research note. The firm says it underestimated the impact of capital equipment demand weakness on Revio placements, as both biotech funding weakness and academic funding uncertainty have resulted in hesitancy to invest in new instruments. It now views PacBio as being “incrementally more sensitive” to the capital equipment downturn.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- PacBio price target lowered to $3.50 from $10 at Canaccord
- PacBio sees FY24 revenue $170M-$200M, consensus $238.67M
- PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
- PacBio plans to reduce annualized operating expense run rate by $50M-$75M
- PacBio reports preliminary Q1 revenue $38.8M, consensus $50.27M